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Refusing to be suppressed
 
On page 737, Fahlén et al. show that colitis-inducing effector T cells that
cannot respond to the suppressive cytokine TGF-
 
 
 
 refuse to be controlled by 
regulatory T (T reg) cells.
Naturally occurring T reg cells suppress the activity of effector CD4
 
 
 
 T cells and 
are essential for the prevention of autoimmune disease and chronic inflammation. 
TGF-
 
 
 
 appears to be required for T reg cell activity, but determining which cells 
produce TGF-
 
 
 
 and which cells respond to it has proven difficult.
Fahlén and colleagues now attempt to define the role of TGF-
 
 
 
 in a mouse model 
of T cell–induced colitis. In this model, colitis can be reversed when CD4
 
 
 
CD25
 
 
 
 T reg 
cells are provided along with the disease-inducing effector cells. The authors showed 
that wild-type T reg cells inhibited the development of colitis induced by wild-type 
effector T cells but failed to prevent disease caused by effector T cells bearing a 
signaling-defective TGF-
 
 
 
 receptor. This demonstrated that effector cells had to be 
responsive to TGF-
 
 
 
 to be controlled by T reg cells. The T reg cells were not required as 
a source of TGF-
 
 
 
, as T reg cells from TGF-
 
 
 
–deficient mice were also able to suppress. 
Thus, T reg cells must be prompting another cell type to produce TGF-
 
 
 
, or may be 
producing a regulatory signal that operates cooperatively with TGF-
 
 
 
.
But did the T reg cells also require TGF-
 
 
 
 signals to induce suppression, as several 
previous studies had shown? The authors found no differences between the T reg 
populations in mice with normal or signaling-defective TGF-
 
 
 
 receptors, and lymph 
node–derived T reg cells from both mice suppressed colitis.
Transfer of splenic T reg cells with mutant TGF-
 
 
 
 receptors, however, 
triggered rather than inhibited colitis. The authors suggest that this can be 
explained by contaminating effector cells that are also mutant for the TGF-
 
 
 
 
receptor and, therefore, cannot be controlled by the inhibitory signal. Thus, the 
requirement for TGF-
 
 
 
 in T reg cell suppression appears to be dictated primarily 
by the effector cells.
T reg cells cannot control colitis if the disease-
inducing effector T cells are unresponsive 
to TGF- .
 
Out with the old, in with the new
 
Muraro et al., reporting on page 805, use stem
An MS lesion (arrow) was 
resolved two years after 
stem cell transplantation.
 
cell transplants to suppress active multiple scle-
rosis (MS), and then show that the treatment in-
creased  the number of naive T cells at the
expense of the memory T cells that are associated
with disease.
Intense immunosuppression followed by
stem cell transplantation has been shown to slow
or stop the formation of new brain lesions in up
to 95% of patients with aggressive MS. Yet it
has been controversial and rarely used, mainly
because immunosuppression is risky and because
nothing was known about how transplantation
induced remission. One proposed theory
was that transplantation might change the
composition of the T cell pool and bias it
away from autoreactivity.
Muraro and colleagues now provide the first
evidence that stem cell transplantation allows
patients to regenerate a new repertoire of T cells
that are less activated and more diverse than
their pretransplant repertoires. This suggests that
 
many of the disease-causing T cells—most of
which have a memory phenotype—were elim-
inated by the treatment.
However, concrete proof that autoreactive
T cells are reduced or eliminated is difficult to
obtain, partly because the specificities of the
autoreactive T cells that invade the central
nervous system are not well defined.
The difficulty in assessing the basis for
treatment success is one problem. Another
is the possibility that autoreactive cells will
reemerge from the pool of transferred stem
cells. The authors agree that these cells
could eventually come back, but hope that
resetting the immune system may improve
the quality of life for patients with an other-
wise poor prognosis.
They emphasize, however, that this intense
therapy is probably only suited to a subset of
MS patients who have active and aggressive
disease and that its implementation will require
careful patient selection.
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